DrugPatentWatch Database Preview

ATOVAQUONE Drug Profile

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

When do Atovaquone patents expire, and what generic alternatives are available?

Atovaquone is a drug marketed by Abhai Llc, Amneal Pharms, Apotex, Glenmark Pharms, Hetero Labs Ltd Iii, Lupin Ltd, Paddock Llc, Glenmark Generics, and Mylan. and is included in nine NDAs.

The generic ingredient in ATOVAQUONE is atovaquone; proguanil hydrochloride. There are sixteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the atovaquone; proguanil hydrochloride profile page.

Summary for ATOVAQUONE

US Patents:	0
Applicants:	9
NDAs:	9
Suppliers / Packagers:	8
Bulk Api Vendors:	111
Clinical Trials:	37
Patent Applications:	3,194
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for ATOVAQUONE
DailyMed Link:	ATOVAQUONE at DailyMed

See drug prices for ATOVAQUONE

Recent Clinical Trials for ATOVAQUONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Richmond Pharmacology Limited	Phase 1
National Center for Parasitology, Entomology and Malaria Control	Phase 4
William Marsh Rice University	Early Phase 1

See all ATOVAQUONE clinical trials

Pharmacology for ATOVAQUONE

Drug Class

Antimalarial Antiprotozoal

Medical Subject Heading (MeSH) Categories for ATOVAQUONE

Anti-Infective Agents

Antimalarials

Enzyme Inhibitors

Synonyms for ATOVAQUONE

1,4-Naphthalenedione, 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-

1,4-Naphthalenedione, 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-, trans-

1,4-Naphthalenedione, 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-

1,4-Naphthalenedione, 2-[cis-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-

1,4-Naphthalenedione, 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy

1,4-naphthalenedione,2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-

137732-39-9

2-((1r,4r)-4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione

2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-nap

2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone

2-(TRANS-4-(4-CHLOROPHENYL)CYCLOHEXYL)-3-HYDROXY-1,4-NAPHTHALENEDIONE

2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione

2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone

2-[4-(4-chlorophenyl)cyclohexy]-3-hydroxy-1,4-naphthoquinone

2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-dihydronaphthalene-1,4-dione

2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone

2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-napthoquinone

2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1.4-naphthoquinone

2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-naphthalene-1,4-dione

2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione

2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxynaphthoquinone, trans-

2-[trans-4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione

2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone

2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione

2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone

2-Hydroxy-3-[4-(4-chlorophenyl)cyclohexyl]-1,4-naphthoquinone

233A184

3-[4-(4-Chlorophenyl)cyclohexyl]-4-hydroxy-1,2-naphthalenedione

3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxy-naphthalene-1,2-dione

3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione

3-[4-(p-chlorophenyl)cyclohexyl]-4-hydroxy-1,2-naphthoquinone

566C

566C80

78668-EP2307343A1

94015-53-9

95233-18-4

AB00053222_04

AB00053222_05

AB00053222-03

AB0012456

AB00513855

AB0107187

AB0211463

AC-30251

AC1L2MZG

AC1Q6E9K

Acuvel

AK544285

AKOS005567953

AKOS015895691

AKOS015961933

AN-6439

AS-12809

Atavaquone

ATO & IL-12

Atovaquone (Atavaquone)

Atovaquone (JAN/USP/INN)

Atovaquone [USAN:BAN:INN]

Atovaquone [USAN:USP:INN:BAN]

Atovaquone & Interleukin 12

Atovaquone EP Impurity B

ATOVAQUONE-D4

Atovaquone, >=98% (HPLC)

BC208879

BCP09477

BDBM192009

BIDD:GT0849

BPBio1_000603

BSPBio_000547

BSPBio_002681

BW 566C

BW 566C-80

BW 566C80

BW-556C-80

BW-566C

BW-566C-80

BW-A 566C

C06835

C22H19ClO3

CAS-95233-18-4

CCG-220534

CCG-39090

CHEBI:575568

CHEBI:95346

CHEMBL222334

CHEMBL519462

Cis-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone

cis-Atovaquone

CRL-8131 & Atovaquone

CS-2702

CTK5H7581

D00236

DB01117

DivK1c_006782

DRG-0084

DSSTox_CID_2629

DSSTox_GSID_22629

DSSTox_RID_76664

DTXSID7022629

FD7252

FT-0081084

FT-0602868

GTPL9695

HMS1569L09

HMS1922F19

HMS2089M14

HMS2093C10

HMS2096L09

HMS2235N08

HMS3369N09

HMS3651N20

HMS3713L09

HSDB 7083

HY-13832

I06-0872

J90007

KB-270797

KBio1_001726

KBio2_002223

KBio2_004791

KBio2_007359

KBio3_001901

KBioGR_001594

KBioSS_002223

KS-00000FO3

KUCQYCKVKVOKAY-CTYIDZIISA-N

KUCQYCKVKVOKAY-OTVXOJSOSA-N

KUCQYCKVKVOKAY-UHFFFAOYSA-N

LS-178256

MCULE-7318126574

Mepron

Mepron (antipneumocystic)

Mepron (TN)

MLS002153863

MolPort-003-666-542

MolPort-006-167-710

NAP016

NCGC00016961-01

NCGC00016961-02

NCGC00016961-03

NCGC00016961-04

NCGC00016961-06

NCGC00016961-07

NCGC00095113-01

NCGC00095113-02

NSC-759582

NSC759582

Pharmakon1600-01504210

Prestwick0_000534

Prestwick1_000534

Prestwick2_000534

Prestwick3_000534

s3079

SBI-0052893.P002

SC-15688

SC-21393

SCHEMBL1542719

SCHEMBL1649508

SCHEMBL21694

SCHEMBL21695

SCHEMBL637069

SCHEMBL9975142

SCHEMBL9975229

SMR001233220

SPBio_001849

SPBio_002468

SpecPlus_000686

Spectrum_001743

SPECTRUM1504210

Spectrum2_001665

Spectrum3_000991

Spectrum4_001117

Spectrum5_001382

SR-05000001438

SR-05000001438-1

SR-05000001438-2

SR-05000001438-4

SR-05000001438-5

STK636160

SW219222-1

Tox21_110714

Tox21_110714_1

trans-2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione

trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone

TX-010638

UNII-Y883P1Z2LT

Wellvone

Y883P1Z2LT

Z1541632806

ZINC100017856

ZINC100345537

ZINC116473771

ZINC12504271

ZINC299873031

Paragraph IV (Patent) Challenges for ATOVAQUONE

Tradename	Dosage	Ingredient	NDA	Submissiondate
MEPRON	SUSPENSION;ORAL	atovaquone	020500	2009-10-20

US Patents and Regulatory Information for ATOVAQUONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abhai Llc	ATOVAQUONE	atovaquone	SUSPENSION;ORAL	210510-001	May 31, 2019	AB	RX	No	No
Paddock Llc	ATOVAQUONE	atovaquone	SUSPENSION;ORAL	207833-001	Apr 28, 2017	AB	RX	No	No
Glenmark Pharms	ATOVAQUONE	atovaquone	SUSPENSION;ORAL	209685-001	Nov 21, 2018	AB	RX	No	No